Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting

Subscriber access provided by UNIV LAVAL

Full Paper

Evolution of a Manufacturing Route to Omarigliptin (MK-3102), A Long-acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes John Y. L. Chung, Jeremy P. Scott, Camille Anderson, Brian Bishop, Nadine bremeyer, Yang Cao, Qinghao Chen, Robert Dunn, Amude Kassim, David Lieberman, Aaron J Moment, Faye Julia Sheen, and Michael J Zacuto Org. Process Res. Dev., Just Accepted Manuscript • DOI: 10.1021/acs.oprd.5b00267 • Publication Date (Web): 01 Oct 2015 Downloaded from http://pubs.acs.org on October 3, 2015

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Organic Process Research & Development is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 31

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Organic Process Research & Development

Evolution of a Manufacturing Route to Omarigliptin (MK-3102), A Long-acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes John Y. L. Chung,*,† Jeremy P. Scott,*,‡ Camille Anderson,§ Brian Bishop,‡ Nadine Bremeyer,‡ Yang Cao,† Qinghao Chen, † Robert Dunn,† Amude Kassim,† David Lieberman,‡ Aaron J. Moment,§ Faye Sheen,‡ Michael Zacuto† †

‡

Department of Process Chemistry, Merck & Co., Inc., P.O. Box 2000, Rahway, NJ, USA;

Department of Process Chemistry, Merck Sharp and Dohme Ltd, Hertford Road, Hoddesdon, EN11 9BU, United Kingdom; §Department of Chemical Process Development & Commercialization, Merck & Co., Inc., P.O. Box 2000, Rahway, NJ, USA

Corresponding Authors [email protected]; [email protected]

ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Table of Contents Graphic


Page 2 of 31

Page 3 of 31

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


ABSTRACT. Development of a convergent synthesis of omarigliptin (MK-3102) suitable for commercial manufacture is described. The target molecule is assembled through a diastereoselective reductive amination of a highly functionalized pyranone with a mesylated pyrazole followed by deprotection of a Boc group. The synthesis of the pyranone relies on three Ru-catalyzed reactions, 1) a DKR reduction of a rac-α-aminoketone to set the two contiguous stereogenic centers, 2) a cycloisomerization of a bis-homopropargylic alcohol to a dihydropyran, and finally 3) a Ru-catalyzed oxidation of a pyranol to the desired pyranone. A regioselective synthesis of an N-Boc-1-mesyl pyrazole fragment was achieved via a base promoted mesyl group isomerisation to afford 30:1 selectivity. A highlight of the endgame process development is telescoping a Boc deprotection and reductive amination followed by direct crystallization of the penultimate from the reaction mixture. This avoids handling of an unstable, mutagenic 1mesylpyrazole BSA salt used in the earlier multi-kilogram deliveries, and improved the overall diastereoselectivity and efficiency of the route.

Keywords: omarigliptin, tetrahydropyran, DKR reduction, cyclosiomerization, dihydropyran, regioselective mesylation



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

INTRODUCTION Type 2 diabetes mellitus is a growing worldwide epidemic affecting more than 366 million people globally, including nearly 26 million people in the United States.1 Commercial proof of concept for dipeptidyl peptidase-4 (DPP-4) inhibitors has been established with Merck’s sitagliptin,2 which was the first once-daily DPP-4 inhibitor approved by the FDA in October 2006. Subsequently, additional DPP-4 inhibitors have entered the marketplace.3 Given the clinical success of DPP-4 inhibitors, there has been interest in generating structurally diverse potent drug candidates with longer half-lives that are amenable to once-weekly dosing. Merck Research Laboratories recently discovered 1 (omarigliptin, MK-3102) (Scheme 1), a highlyfunctionalized and structurally differentiated long-acting DPP-4 inhibitor,4 that recently received marketing authorisation in Japan for the once-weekly treatment of type 2 diabetes. A scalable, first generation synthesis of a forerunner of 1, namely 2, which differs only by a mesyl group, was recently reported.5 We adopted similar chemistry for the initial kilogram deliveries of 1 by mesylation of 3 followed by Boc deprotection. Although the process was productive and capable of supporting the program through development, this was not a process that met our standards for commercial manufacture. Significant improvements were made to the first generation synthesis of Boc-ketone 5 to improve the robustness and reduce both process mass intensity and cost of goods. Herein we report the evolution and development of an efficient process for multikilogram scale synthesis of omarigliptin amenable to manufacturing scale.

Scheme 1. Retrosynthetic analysis of omarigliptin (1)


Page 4 of 31

Page 5 of 31

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


RESULTS AND DISCUSSION Initial multi-kilogram deliveries of omarigliptin (1). A critical evaluation of the endgame of the Discovery Chemistry route indicated that the most salient issue to be addressed was the lack of regiochemical control over the N-sulfonation of the pyrazole moiety embedded within 1 (Scheme 2). An approximately 1:1 mixture of the two N-sulfonated regiochemical isomers 14 and 15 was typically obtained when using NaH and MsCl to sulfonate 13 requiring chromatographic purification,6 an operation that becomes prohibitive as the scale of operation increases. In addition, as kilogram quantities of the unprotected pyrazole 7 were available for these initial multikilogram deliveries, it was desirable to directly use 7 without the need to reprotect with a Boc group to access 13. Consequently, we set out to develop a regiochemical sulfonation of the known intermediate 3,5 which could be accessed by diastereoselective reductive amination of pyranone 5 with pyrazole 7 (Scheme 1).

Scheme 2. Discovery chemistry pyrazole N-sulfonation



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Our first kilogram delivery began with the reductive amination of pyranone 5 with pyrazole 7 which was modified from the previously reported conditions (Scheme 3).5 Specifically a switch of solvent from DMAC to DMF was made to suppress formation of the acetylated impurity 17 which was observed to form during the subsequent sulfonation step and was attributed to the presence of low levels of residual DMAC within the isolated 3. Under these modified conditions, the desired 4 was isolated by direct crystallization from the reaction mixture in 80% yield and with 4.5 A% of the undesired diastereomer present. The diastereoselectvity of the reduction was 16:1.

Scheme 3. First multi-kilogram delivery of omarigliptin (1)

With intermediate 3 in hand, screening of the mesylation indicated that amine bases such as Et3N and pyridine when used in combination with mesyl chloride favored the undesired


Page 6 of 31

Page 7 of 31

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


regioisomer 16 with as high as 9:1 selectivity. Moving to stronger K and Na metal bases provided more encouraging results with selectivities as high as 1:8 favoring the desired isomer 4 under certain conditions. A key observation was made when using NaHMDS that the selectivity of the reaction improved as long as there remained some 3 present within the reaction mixture (or more specifically the Na anion of 3, vide infra). Once all of 3 had been consumed to 4 and 16, no further change in the ratio of 4:16 occurred on extended aging. Application of DOE to one set of reagents (NaHDMS as base, MsCl as mesylating agent in DMF) indicated that the regioselectivity was not directly dependent on concentration, temperature or reagent equivalents. In addition, the regioselectivity was not dependent on the age time when preforming the anion prior to MsCl addition. A slow addition of MsCl resulted in high regioselectivity for the desired 4 (up to 1:68 in favor of 4 in the reaction mixture). Our mechanistic hypothesis for these observations is that the undesired 16 can serve as a mesylating agent under the reaction conditions and undergoes turnover to the more thermodynamically stable isomer 4. Optimized conditions required a balance between the amount of unconverted 3 left over at the end of reaction and achieving a high regioselectivity for the penultimate intermediate 4. Ultimately for this first kilogram delivery, conditions of 2.0 equiv. NaHMDS and 1.75 equiv. MsCl in DMF were used with the addition of MsCl occurring over 4-6 h. The desired 4 crystallized toward the end of addition and following addition of water as antisolvent, could be isolated in 74% yield (96 A% purity) with the regioisomer 16 present at just 0.1 A%. Deprotection of the Boc group within 4 proved challenging. This was due to competitive cleavage of the mesyl group to form the undesired byproduct 2. From a screen of acid and solvent combinations, benzenesulfonic acid (BSA) in dichloromethane as solvent emerged as the most promising with levels of 2 suppressed to around 3.0 A% in the reaction mixture. Extended



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

aging led to an increase in the level of 2 and as such the reaction was typically quenched with around less than 2.0 A% of 4 remaining. A further impurity that proved problematic was formation of the N-benzenesulfonated 18 which occurred during basification in the workup and is speculated to occur by besylation with the mixed anhydride formed from benzenesulfonic acid and the mesyl portion cleaved from 4. The final level of 18 was ultimately controlled through a recrystallization, and application of the deprotection conditions afforded crude omarigliptin (1) in 78% yield (1.7 A% 18), followed by a recrystallisation from EtOAc to give pure 1 in 72% yield with 1.0 A% of 18 present. In a subsequent kilogram campaign, the addition of water (0.2 wt%) was found to suppress the formation of 18 and omarigliptin could be isolated in an improved 73% yield without the need for a recrystallization (vs 56% for the previous campaign).

Process development for manufacturing scale. Whilst significant progress to solving the Nsulfonation regiochemical problem was made during the first kilogram campaign to 1, specifically on the fully elaborated intermediate 3, it was considered desirable to move back to the more convergent approach, wherein mesylated pyrazole 8 is coupled with pyranone 5, followed by a final Boc deprotection to form omarigliptin (Scheme 1). In so doing, we expected to be able to utilise our knowledge gained in the sulfonation of 3 to the pyrazole 13 and turnover any of the undesired regioisomer 15 that might form to 14. In addition, focused process development on other steps on the routes to pyrazole 8 and pyranone 5 were pursued to reduce cost, improve processability and scalability, and address safe handling as well as other aspects associated with readiness for manufacturing scale operations.


Page 8 of 31

Page 9 of 31

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Process development of Boc-mesyl-pyrazole 8 for manufacturing scale. Before embarking on the development of the selective mesylation of 13, we needed a scalable synthesis of this intermediate.

The discovery chemistry route to 13 (Scheme 4, Route A), employed high

temperatures, excess N,N-dimethylformamide dimethylacetal (DMF•DMA),7 silica gel chromatography, and a Boc reprotection which were all undesirable. We undertook process development to address these issues, and the revised process to 13 (Scheme 4, Route B) used lower reaction temperatures, fewer equivalents of DMF•DMA, eliminated the silica gel chromatography and utilized mild dehydration conditions to retain the Boc group. In addtion, the levels of mutagenic impurities (such as hydrazine, methyl tosylate) in the downstream steps were estimated through purge factor calculations8 and/or confirmed by analysis to be significantly below Threshold of Toxicological Concern (TTC) levels.

Scheme 4. Evolution of the synthesis of Boc Pyrazole 13

Building on the discovery of the regioselective sulfonation of intermediate 3, whereby an initially formed mixture of regioisomers was converged to the desired isomer 4, we sought to develop a related process for the sulfonation of Boc-pyrazole 13 (Scheme 5). Whilst application of our previously developed NaHMDS/MsCl conditions was studied first, unacceptably high



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 10 of 31

levels of starting material 13 were typically present and only a 63% yield of 14 was obtained with a 9:1 regioselectivity. Following screening, a telescoped through process was developed whereby a kinetic mesylation with MsCl/Et3N was carried out in 2-MeTHF to afford a quantitative combined yield of 14 and regioisomer 15 favoring 15 in a 5:1 ratio. Following an aqueous workup to remove triethylamine salts and azeotropic drying, addition of 7 mol% of solid tBuOK to the mixture afforded turnover to a 30:1 mixture favoring the desired 14. Following a recrystallization of the isolated solids, 14 was obtained in 84% yield from 13 and with 99% ee and 93% assay yield respectively. This catalyst proved to be highly active and robust such that we could reduce the catalyst loading from 0.5 to 0.1 mol% without sacrifying selectivity and reaction kinetics. We found it was critical to apply efficient N2 sparging during the reaction to remove CO2, otherwise the reaction could stall is this was



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 12 of 31

allowed to accumulate. It is hypothesized that the tethered catalyst reduced the dissociation tendency of the arene from the Ru relative to the first generation catalyst which in conjunction with increased steric hinderance of the linker contributed to improved stereoselectivity, activity and robustness. The DKR product 6 work up stream was taken directly into the Ru-catalyzed cycloisomerization step without isolation as previously reported. In order to ensure consistent reaction kinetics and purity profiles in the downstream chemistry, we incorporated activated carbon and silica slurry treatments to the work up streams of DKR product 6 and cycloisomerization product 7 respectively. Compound 7 was then isolated by crystallization. With these treatments, the subsequent hydroboration of 7 and the RuCl3-catalyzed oxidation of the resulting 23 proceeded smoothly. Boc Ketone 5 was crystallized directly from reaction mixture in good purities and Ru levels in 23 and 5 were

Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting

Recommend Documents